Aardvark Therapeutics, Inc. (AARD) announced Tuesday its participation in the 2025 United in Hope Conference for Prader-Willi syndrome or PWS on June 24-28 in Phoenix, Arizona.
The company will present previously disclosed Phase 2 data from its clinical trial evaluating ARD-101, an oral small-molecule therapy aimed at reducing hyperphagia or pathologic hunger in patients with PWS.
Aardvark will deliver both a poster and a five-minute oral presentation highlighting ARD-101's favorable safety profile and early efficacy signals observed in the Phase 2 study. Based on the results, the company has designed the ongoing Phase 3 HERO trial and started enrolling patients with PWS.
In addition, Aardvark's Chief Medical Officer Manasi Jaiman will participate in a clinician panel discussion.
ARD-101 is designed to suppress hunger-specific pathways that differ from appetite mechanisms, offering a new potential treatment strategy for PWS and other metabolic conditions.
Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, to address limitations of current GLP-1 therapies for obesity.
Currently, AARD is trading at $14.61, up by 9.64 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.